Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

UHT

Universal Health Realty Income Trust Q1 2026 Earnings Beat

Universal Health Realty Income Trust reported first-quarter 2026 net income of $5.0 million, or $0.36 per diluted share, up from $4.8 million, or $0.34 per diluted share, in the same period a year earlier.

The company said the $242,000 increase in net income came mainly from a $217,000 decline in interest expense, driven primarily by a lower average effective borrowing rate, including the effect of interest rate swap agreements. A further $25,000 increase came from higher income at various properties.

Funds from operations rose to $12.3 million, or $0.88 per diluted share, from $11.9 million, or $0.86 per diluted share, in the first quarter of 2025. That was an increase of $336,000, or $0.02 per diluted share, reflecting the higher net income and a rise in depreciation and amortization expense.

The company declared a first-quarter dividend of $0.745 per share, totaling $10.3 million, and paid it on March 31, 2026.

In April, the company amended its credit agreement, lifting borrowing capacity to $475 million from $425 million. The maturity date remained Sept. 30, 2028, with options to extend it for two additional six-month periods. As of March 31, 2026, borrowings outstanding stood at $359.5 million.

The company also advanced its Miller Medical Plaza project in Palm Beach Gardens, Florida. Construction began in February 2026 on the 80,000-square-foot medical office building, which is expected to cost about $34 million and be completed in the fourth quarter of 2026. A 10-year master flex lease has been signed for about 75% of the rentable square feet, with the lease starting when the building is completed. Today the company's shares have moved 0.2% to a price of $40.77. For the full picture, make sure to review UNIVER's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS